LENZ Therapeutics Inc (LENZ)vsModerna Inc (MRNA)
LENZ
LENZ Therapeutics Inc
$4.81
+0.63%
HEALTHCARE · Cap: $147.05M
MRNA
Moderna Inc
$142.77
-4.60%
HEALTHCARE · Cap: $57.00B
Smart Verdict
WallStSmart Research — data-driven comparison
Moderna Inc generates 10275% more annual revenue ($2.23B vs $21.48M). LENZ leads profitability with a 0.0% profit margin vs -141.4%. LENZ earns a higher WallStSmart Score of 35/100 (F).
LENZ
Hold35
out of 100
Grade: F
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LENZ.
Margin of Safety
+70.0%
Fair Value
$135.25
Current Price
$142.77
$7.52 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Trading at 8.4x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : LENZ
The strongest argument for LENZ centers on Price/Book, Debt/Equity, Altman Z-Score.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : LENZ
The primary concerns for LENZ are EPS Growth, Market Cap, Profit Margin.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
LENZ profiles as a value stock while MRNA is a turnaround play — different risk/reward profiles.
LENZ carries more volatility with a beta of 1.63 — expect wider price swings.
LENZ is growing revenue faster at 9.7% — sustainability is the question.
LENZ generates stronger free cash flow (-39M), providing more financial flexibility.
Bottom Line
LENZ scores higher overall (35/100 vs 21/100). MRNA offers better value entry with a 70.0% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
LENZ Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
LENZ Therapeutics Inc is a cutting-edge biopharmaceutical company dedicated to developing transformative therapies for neurological disorders, specifically targeting critical unmet needs in the central nervous system (CNS). The company employs advanced drug formulation and delivery technologies to support a robust pipeline of proprietary assets, aiming to enhance patient outcomes and address significant healthcare challenges. With a strong focus on strategic partnerships and a commitment to rigorous clinical research, LENZ is strategically positioned for significant growth and aspires to become a key player in the biopharmaceutical landscape, leveraging emerging opportunities in the dynamic healthcare market.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?